Thousand Oaks-based Amgen completed its $13.4 billion cash acquisition of anti-inflammation drug Otezla Nov. 21, in a deal that cleared the way for Bristol Meyers Squibb to finalize its acquisition of Celgene. The Federal Trade Commission announced Nov. 15 that it would require Celgene to spin off the drug before approving the $74 billion merger…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
